Leicester, 23 April 2026
Upperton Wins Two Awards at Medilink Midlands
Upperton has been announced as a dual winner at this year’s Medilink Midlands Awards, securing both the Outstanding Achievement Award. Additionally, Upperton won the Innovation in Service Delivery Award. This years double win marks the company’s continued growth, operational excellence and use of cutting-edge technology to deliver on client projects.
The double win marks another milestone in Upperton’s journey and reinforces its position as a truly innovative and fast-growing company within the East Midlands, and the wider CDMO sector. Upperton’s latest success highlights a pattern of consistent performance and long-term investment rather than a single moment of achievement.
Winning the Outstanding Achievement Award reflects a year of significant progress for Upperton. This was driven by strategic expansion into sterile manufacturing under stringent Annex-1 guidelines and sustained business growth. Additionally, an unwavering focus on quality, and exceptional client outcomes helped to secure the win. The award was sponsored by Pioneer Group, and recognises organisations that have demonstrated exceptional performance across multiple areas of operation. For Upperton, it represents months of outstanding work across our business.
Commenting on the achievement, Upperton’s CEO, Nikki Whitfield, said:
“To be recognised with not one, but two awards at the Medilink Midlands Awards is an incredible honour for Upperton. These awards reflect the commitment, expertise and passion of our people, and the strong partnerships we have built with our clients. We have always focused on creating a truly exceptional service for small to medium sized biotechs, and this recognition is a proud moment that reinforces our dedication to them.”
Upperton’s win in the Innovation in Service Delivery category acknowledges their outstanding delivery of pharmaceutical development and manufacturing services. The award was sponsored by MDTi, celebrating organisations that challenge convention. They also recognise companies that introduce new, cutting-edge technology that make a considerable difference to client delivery.
The recognition from Medilink Midlands also reflects Upperton’s strong regional roots and contribution to the UK life sciences ecosystem. Operating from its award-winning facilities in Nottingham, the company continues to invest in local talent. Meanwhile, they also collaborate with academic, clinical and industrial partners across the region and beyond in addition to working with global companies that shape the future of healthcare.
Expansion of Service Delivery
This latest recognition comes at a time when Upperton is continuing to broaden its offering. They are dedicated to supporting small to medium sized biotech companies with end-to-end CDMO services, across a range of dosage forms. As the industry faces mounting pressure to deliver medicines faster and more efficiently, Upperton’s combination of technical expertise, collaborative culture and innovative service delivery positions it as a trusted partner in navigating this complexity.
The dual award win serves as a moment to reflect on progress while looking ahead with confidence. As Upperton moves forward, the focus remains firmly on sustainable growth, ongoing innovation and the continued evolution of services. In doing so, meeting the needs of a rapidly changing pharmaceutical landscape. Being recognised once again by Medilink Midlands is both an honour and a powerful endorsement of Upperton’s strategy. Meanwhile, it also recognises its people, and its commitment to shaping the future of pharmaceutical development and manufacturing.
-ENDS-
Notes to editors:
About Upperton Pharma Solutions:
Upperton has over 27 years’ experience of delivering science-led, high quality, innovative drug development and manufacturing solutions to pharmaceutical and biotechnology clients worldwide.
Based in Nottingham, UK, Upperton has a 60,000 sq. ft development and manufacturing facility, with formulation and analytical development laboratories, alongside a fully equipped GMP manufacturing and quality control testing capability. Upperton is MHRA Approved to manufacture materials for clinical trial supplies. In addition to supporting conventional oral solid dosage form development, Upperton has a strong history in spray drying which addresses both the challenges with poorly soluble molecules and as a particle engineering technology for targeted deposition for pulmonary and nasal drug products.
The company employs over one hundred highly skilled personnel and has its headquarters in Nottingham, UK.
For further information, images, and interview opportunities, please contact:
Rob Halliwell, Associate Director of Marketing, Upperton
rob.halliwell@upperton.com
upperton.com